Z-ligustilide:一种潜在的治疗药物用于动脉样硬化复杂的脑血管疾病
Longyu Shen1, Qianqian Tian2, Qiqi Ran1
1School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Biomolecules
|January 8, 2025
概括
来自传统草药的Z-ligustilide (Z-LIG) 在治疗动脉样硬化 (AS) 和相关的大脑血管疾病方面表现有前途. 它提供神经保护,并改善诸如缺血性中风等疾病的结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 心血管医学 心血管医学
背景情况:
- 动脉样硬化 (AS) 是缺血性脑血管疾病的主要原因,死亡率和疾病负担增加.
- Z-ligustilide (Z-LIG) 是Angelica sinensis和Ligusticum chuanxiong中的一个关键化合物.
研究的目的:
- 审查Z-LIG在AS和脑血管并发症中的物理化学性质,药理动力学和治疗机制.
- 为开发Z-LIG作为AS的干预药物提供基础.
主要方法:
- 对Z-LIG的特性和机制的文献综述.
- 分析Z-LIG对脂质代谢,氧化应激,炎症和血管健康的影响.
- 对Z-LIG在缺血性中风,TIA和VaD中的神经保护作用的评估.
主要成果:
- Z-LIG 改善脂质代谢,表现出抗氧化和抗炎作用,并保护血管内皮.
- 它抑制了血管纤维化,加厚,在AS中抑制了斑块化.
- 在脑血管疾病中,Z-LIG通过抗神经炎症,抗氧化和血脑屏障保护来证明神经保护.
结论:
- 对于AS及其脑血管并发症,Z-LIG具有多方面的治疗机制.
- 它的神经保护作用在诸如缺血性中风,TIA和血管痴呆等疾病中显著.
- 对Z-LIG的进一步研究可能会导致针对AS和相关疾病的新型治疗策略.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
529
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
529
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
452
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
452
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
770
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
770
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
405
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
405
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381